Before starting Auvelity for dementia agitation, ask the doctor whether the behavior is truly agitation associated with Alzheimer’s disease, whether pain or illness could be causing it, what specific improvement treatment should produce, and how the person’s medications and medical history affect the risks. Also ask about dosing, falls, blood pressure, seizures, drug interactions, monitoring, and the conditions under which treatment should be reduced or stopped. For example, new shouting and resistance to care may look like dementia-related agitation but actually reflect a urinary tract infection, constipation, or an untreated toothache. Auvelity combines dextromethorphan and bupropion. The U.S.
Food and Drug Administration approved it for agitation associated with dementia due to Alzheimer’s disease, but it is not an as-needed medication for calming an isolated episode. It is taken on a scheduled basis and does not treat memory loss or alter the underlying course of Alzheimer’s disease. The diagnosis therefore matters: evidence supporting its approved use should not automatically be extended to agitation caused by another dementia, delirium, medication toxicity, or an unsafe environment. FDA prescribing information A family member or regular caregiver should usually participate in the discussion when the person with dementia permits it or lacks the capacity to manage treatment independently. That caregiver may be the person who notices whether pacing becomes less frequent, dizziness appears after a dose increase, or confusion worsens. A written list of medications and a short behavior diary can make the appointment more useful than a general report that the person has been “difficult.”.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Is Auvelity Appropriate for This Type of Dementia Agitation?
- What Benefits Can Auvelity Realistically Provide?
- Which Medical Conditions Could Make Auvelity Unsafe?
- How Will Dosing and Monitoring Work at Home?
- Which Drug Interactions and Side Effects Need Special Attention?
- What Non-Drug Measures Should Continue During Treatment?
- What Is the Plan for Worsening Symptoms, Emergencies, or Stopping?
- Frequently Asked Questions
Is Auvelity Appropriate for This Type of Dementia Agitation?
Ask, “What makes you think this is agitation associated with Alzheimer’s disease, and what other causes have been ruled out?” Agitation can include excessive motor activity, pacing, verbal aggression, or physical aggression, but the label does not explain why the behavior is occurring. A sudden change over hours or days should prompt consideration of delirium and medical problems such as infection, dehydration, urinary retention, constipation, medication effects, sleep disruption, or pain. The timing and setting of the behavior can offer important clues. A person who becomes distressed only during bathing may be cold, frightened, in pain, or overwhelmed by several instructions at once.
Someone who begins wandering and hallucinating shortly after a medication change needs a medication and medical review, not an automatic assumption that Alzheimer’s disease has progressed. The Alzheimer's Association recommends checking for discomfort, hunger, thirst, fatigue, infection, skin irritation, and environmental triggers. Ask whether the person’s dementia diagnosis is sufficiently established and whether the treatment evidence fits that diagnosis. Auvelity’s agitation indication is specifically for dementia due to Alzheimer’s disease. If the person has Lewy body dementia, vascular dementia, frontotemporal dementia, mixed dementia, or an uncertain diagnosis, the doctor should explain the evidence, limitations, and rationale before prescribing it.
What Benefits Can Auvelity Realistically Provide?
Ask the doctor to identify one or two target behaviors that can be observed and measured. “Less agitation” is vague; “physical aggression during evening care decreases from five episodes a week to one” is more useful. Other practical targets might include fewer attempts to leave the home, shorter periods of repetitive yelling, or the ability to complete dressing without hitting a caregiver. In a five-week placebo-controlled study cited in the FDA label, Auvelity produced a statistically greater improvement on the Cohen-Mansfield Agitation Inventory than placebo.
The difference between treatment groups was smaller than the total improvement seen in either group, so statistical benefit does not guarantee a dramatic or personally meaningful response for every patient. Trial participants had moderate-to-severe agitation judged to require medication, and the study’s limited duration cannot answer every question about long-term effectiveness or safety. Ask, “How long should we try it before deciding whether it helps, and what degree of change would justify continuing?” The doctor may use caregiver observations, a behavior frequency chart, or a structured rating scale. Without a baseline, natural fluctuations can be mistaken for a drug response; one unusually calm weekend is not the same as sustained improvement across several weeks.
Which Medical Conditions Could Make Auvelity Unsafe?
Ask specifically about seizure risk. Auvelity is contraindicated in people with a seizure disorder, a current or previous diagnosis of anorexia nervosa or bulimia, or abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs. Severe head injury, severe stroke, low sodium, low oxygen, certain metabolic problems, and medicines that lower the seizure threshold may add risk. A caregiver should not abruptly stop a long-standing sedative merely to simplify the medication list before Auvelity is started. Blood pressure should be assessed before treatment and monitored periodically because bupropion can cause hypertension.
Ask whether home readings are needed and what number should trigger a call. For example, a patient with poorly controlled hypertension who becomes more restless and develops headaches after starting treatment needs assessment rather than an assumption that the symptoms are part of dementia. The doctor should also review personal or family history of bipolar disorder, mania, or hypomania, as well as hallucinations, delusions, and other psychiatric symptoms. Auvelity may activate mania or produce other neuropsychiatric reactions in susceptible people. Untreated anatomically narrow eye angles are another concern because bupropion-related pupil dilation can precipitate angle-closure glaucoma; sudden eye pain, halos around lights, visual change, or eye redness requires urgent evaluation.
How Will Dosing and Monitoring Work at Home?
Ask the doctor or pharmacist to write down the exact titration schedule. For Alzheimer’s agitation, FDA labeling starts with 30 milligrams of dextromethorphan and 105 milligrams of bupropion once each morning. Based on tolerability, the schedule increases on day eight to that strength twice daily, at least eight hours apart, and on day 15 to a maximum of 45/105 milligrams twice daily, also at least eight hours apart. Tablets must be swallowed whole rather than crushed, split, or chewed. That schedule creates a practical tradeoff. Gradual increases allow time to detect dizziness, sleepiness, stomach upset, or confusion, but they require dependable medication administration.
A person who cannot swallow extended-release tablets or who frequently refuses a second dose may need a different plan. Ask what to do after a missed dose; caregivers should not improvise by doubling the next dose. Kidney function, metabolism, and interacting medicines can change the maximum dose. For moderate renal impairment, known CYP2D6 poor metabolizers, or use with a strong CYP2D6 inhibitor, the labeled maximum for Alzheimer’s agitation is once-daily 45/105 milligrams after the initial lower strength. Auvelity should be avoided in severe hepatic impairment. Ask who will review blood pressure, kidney and liver information, falls, sleepiness, behavior logs, and treatment benefit after each increase.
Which Drug Interactions and Side Effects Need Special Attention?
Bring every prescription, over-the-counter product, supplement, and as-needed medication to the review. Auvelity contains ingredients that can also appear in other products: dextromethorphan is common in cough remedies, while bupropion is prescribed for depression and smoking cessation. Accidental duplication can raise the risk of seizures, confusion, and other dose-related reactions. Monoamine oxidase inhibitors, or MAOIs, are contraindicated during Auvelity treatment and within specified washout periods. The restriction also applies to certain medical treatments with MAOI activity, including linezolid and intravenous methylene blue.
Serotonergic medicines, including some antidepressants, can increase the risk of serotonin syndrome. Restlessness, fever, sweating, tremor, overactive reflexes, muscle jerking, blood-pressure changes, or altered mental status after a medication change warrants prompt medical attention. Dizziness and sleepiness matter particularly in dementia care because they can turn a manageable balance problem into a fall. In the five-week Alzheimer’s agitation study, dizziness occurred in 9% of Auvelity-treated participants and 3% of placebo recipients; somnolence occurred in 8% and 4%, respectively. Dyspepsia, fatigue, nausea, constipation, psychotic symptoms, and confusional states were also reported. The warning is practical: a patient who becomes calmer but starts falling on the way to the bathroom may not have achieved an acceptable treatment tradeoff.
What Non-Drug Measures Should Continue During Treatment?
Ask which non-drug strategies should remain in place and how consistently they should be used. Environmental adjustments, predictable routines, simple communication, adequate sleep, pain management, meaningful activity, and reduced noise can address triggers that medication cannot. If a person paces every afternoon when the television is loud and the room is crowded, moving to a quiet space or taking a supervised walk may help even after Auvelity is prescribed.
Medication should not become a substitute for investigating distress. The Alzheimer's Association's behavioral-treatment guidance recommends non-drug approaches first and careful medication use when symptoms remain severe or create a risk of harm. Keeping routines stable during a medication trial also makes it easier to judge whether improvement is attributable to the drug.
What Is the Plan for Worsening Symptoms, Emergencies, or Stopping?
Ask for written instructions distinguishing expected side effects from urgent problems. A seizure, severe allergic reaction, possible serotonin syndrome, sudden painful visual disturbance, or rapidly worsening mental status requires immediate medical evaluation. New hallucinations, marked disorientation, repeated falls, severe agitation, or a substantial blood-pressure increase should prompt a timely call to the prescriber rather than waiting for the next routine visit.
Auvelity is not labeled as an as-needed rescue treatment, so caregivers should ask what to do during a dangerous episode and when emergency services are appropriate. The care plan should also state when lack of benefit justifies discontinuation and whether the prescriber wants a particular stopping schedule. A dated log recording each dose, agitation episode, fall, blood-pressure reading, and new symptom gives the clinician concrete information for that decision.
Frequently Asked Questions
Is Auvelity approved for every form of dementia agitation?
No. Its FDA indication covers agitation associated with dementia due to Alzheimer’s disease. A clinician considering it for another dementia should explain that the use falls outside this specific indication and discuss the limits of available evidence.
Can Auvelity be given only when agitation becomes severe?
No. The prescribing information states that it is not indicated for as-needed, or “PRN,” treatment of Alzheimer’s agitation. It follows a scheduled dosing and titration plan.
Does Auvelity slow Alzheimer’s disease?
Auvelity treats the symptom of agitation. It is not approved to slow the underlying neurodegenerative disease or restore lost memory and thinking abilities.
Should a caregiver check over-the-counter cough medicines?
Yes. Many cough and cold products contain dextromethorphan, one of Auvelity’s two active ingredients. The prescriber or pharmacist should review these products to prevent unintended duplication and interactions.
What should be tracked after treatment begins?
Track the frequency and severity of target behaviors, dose times, missed doses, dizziness, sleepiness, falls, confusion, hallucinations, digestive symptoms, blood-pressure readings when requested, and any change in daily function.
